Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969387 | 0.87 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL26020661 | 0.85 | IDO1 (0.45) | IDO1EPHX2PPARGSLC6A2SLC6A4 | |
| SCHEMBL26020762 | 0.77 | IDO1 (0.38) | IDO1SLC6A2SLC6A4P2RX7 | |
| SCHEMBL17071866 | 0.74 | IDO1 (0.56) | IDO1EPHX2PPARGSLC6A2SLC6A4 | |
| SCHEMBL13020830 | 0.74 | IDO1 (0.43) | IDO1SLC6A2SLC6A4P2RX7 | |
| SCHEMBL20468369 | 0.71 | AR (0.43) | HDAC3HDAC1HDAC2HDAC6PDE3B | |
| SCHEMBL12107918 | 0.71 | CNR1 (0.41) | IDO1 | |
| SCHEMBL22445529 | 0.71 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL28763543 | 0.71 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL7782539 | 0.71 | IDO1 (0.61) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | IDO1 184/4885EPHX2 3315/4885PPARG 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.